Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

721. Usefulness of chronotropic incompetence in response to exercise as a predictor of myocardial infarction in middle-aged men without cardiovascular disease (Abstract)

Usefulness of chronotropic incompetence in response to exercise as a predictor of myocardial infarction in middle-aged men without cardiovascular disease An attenuated heart rate (HR) response to exercise, or chronotropic incompetence, has been shown to predict adverse cardiac events in subjects without known cardiovascular disease (CVD). The aim of the present study was to investigate whether chronotropic incompetence independently predicts acute myocardial infarction (AMI) in middle-aged men

2008 EvidenceUpdates

722. The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study Full Text available with Trip Pro

The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study The association of smoking with cardiovascular diseases in populations with low cholesterol levels is unclear and this lack of clarity may have contributed to the very high prevalence of smoking in East Asian men. The effect of smoking on stroke subtypes is particularly unclear.We used data from a prospective (...) value for this population as among those with higher levels. There was no association of smoking with intracerebral hemorrhage. Smoking accounted for 20% of all cardiovascular disease outcomes in this population.Smoking is a major risk factor for cardiovascular diseases in populations with low cholesterol levels and global interventions are required to halt the emerging tobacco epidemic in low- and middle-income countries.

2008 EvidenceUpdates

723. All-cause and Cardiovascular Disease Mortality Increased With Metabolic Syndrome in Taiwanese (Abstract)

All-cause and Cardiovascular Disease Mortality Increased With Metabolic Syndrome in Taiwanese This study aimed to investigate the relationship between mortality and metabolic syndrome using the America Heart Association/National Heart Lung Blood Institute (AHA/NHLBI) and International Diabetes Federation (IDF) definitions in a Taiwanese cohort.A total of 124,513 participants, aged 20-94 years, from four nationwide health centers in Taiwan were recruited from 1998 to 1999. Cox proportional (...) hazard regression analyses were used to estimate the relative risks (RRs) for all-cause and cardiovascular disease (CVD) mortality for those with metabolic syndrome compared to those without metabolic syndrome over 8 years of follow-up.The baseline prevalence of metabolic syndrome was 22.4% by the AHA/NHLBI and 13.9% by the IDF definition. A total of 2,762 deaths (527 CVD) occurred. Using the AHA/NHLBI definition, the RRs (95% confidence intervals) of all-cause and CVD mortality were 1.21 (1.09-1.34

2008 EvidenceUpdates

724. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Full Text available with Trip Pro

Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Around 80% of all cardiovascular deaths occur in developing countries. Assessment of those patients at high risk is an important strategy for prevention. Since developing countries have limited resources for prevention strategies that require laboratory testing, we assessed if a risk prediction method that did not require any laboratory tests could (...) be as accurate as one requiring laboratory information.The National Health and Nutrition Examination Survey (NHANES) was a prospective cohort study of 14 407 US participants aged between 25-74 years at the time they were first examined (between 1971 and 1975). Our follow-up study population included participants with complete information on these surveys who did not report a history of cardiovascular disease (myocardial infarction, heart failure, stroke, angina) or cancer, yielding an analysis dataset N=6186

2008 Lancet

725. Lipoprotein(a) and Cardiovascular Disease in Ethnic Chinese: The Chin-Shan Community Cardiovascular Cohort Study Full Text available with Trip Pro

Lipoprotein(a) and Cardiovascular Disease in Ethnic Chinese: The Chin-Shan Community Cardiovascular Cohort Study Little is known about lipoprotein(a) [Lp(a)] as a predictor of vascular events among ethnic Chinese. We prospectively investigated the association of Lp(a) with cardiovascular disease and all-cause death in a community-based cohort.We conducted a community-based prospective cohort study of 3484 participants (53% women; age range, 35-97 years) who had complete lipid measurements (...) and were free of a cardiovascular disease history at the time of recruitment. Over a median follow-up of 13.8-years, we documented 210 cases of stroke, 122 cases of coronary heart disease (CHD), and 781 deaths.The incidences for each event increased appreciably with Lp(a) quartile for stroke and all-cause death, but not for CHD. Baseline Lp(a) concentration by quartile was not significantly associated with stroke, all-cause death, and CHD in multivariate analyses. The multivariate relative risk

2008 EvidenceUpdates

726. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease Full Text available with Trip Pro

Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease BACKGROUND: Higher levels of red blood cell distribution width (RDW) may be associated with adverse outcomes in patients with heart failure. We examined the association between RDW and the risk of all-cause mortality and adverse cardiovascular outcomes in a population of people with coronary disease who were free of heart failure at baseline. METHODS AND RESULTS: We performed a post (...) mortality (hazard ratio per percent increase in RDW, 1.14; 95% confidence interval, 1.05 to 1.24). After categorization based on quartile of baseline RDW and further adjustment for hematocrit and other cardiovascular risk factors, a graded independent relation between RDW and death was observed (P for trend=0.001). For instance, participants with RDW in the highest quartile had an adjusted hazard ratio for death of 1.78 (95% confidence interval, 1.28 to 2.47) compared with those in the lowest quartile

2008 EvidenceUpdates Controlled trial quality: predicted high

727. A prospective community-population-registry based cohort study of the association between betel-quid chewing and cardiovascular disease in men in Taiwan (KCIS no. 19) Full Text available with Trip Pro

A prospective community-population-registry based cohort study of the association between betel-quid chewing and cardiovascular disease in men in Taiwan (KCIS no. 19) Betel-quid chewing, a recognized risk factor for oral cancer, was shown to be a contributory cause of metabolic syndrome in humans, which implies a greater likelihood of developing cardiovascular disease (CVD) among those with the betel habit.This study investigated the effect of betel chewing on the risk of developing overt (...) CVD.We used the prospective cohort data derived from a community-population-registry-based integrated screening program to quantify the effect of betel-quid chewing on the incidence of newly diagnosed CVD by classifying the study population into either exposed or nonexposed groups according to chewing status at baseline. We then followed the group free of CVD at recruitment for 2.72 y (SD=1.52 y) to learn of new cardiovascular events. Proportional hazards regression modeling was used to estimate

2008 EvidenceUpdates

728. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study (Abstract)

of a model that included Framingham Heart Study score factors, metabolic syndrome components, and fibrinogen levels.Serum uric acid levels are an independent predictor of death in patients at high risk of cardiovascular disease. Further studies are warranted to evaluate its prognostic implications and potential utility in the monitoring of therapy. (...) Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study Uric acid is a product of the activity of xanthine oxidase, an enzyme linked to oxidative stress, endothelial dysfunction, and heart failure. It is unclear whether adding uric acid levels to the assessment of cardiovascular risk might contribute to the improved ability to stratify cardiovascular risk

2008 EvidenceUpdates

729. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. Full Text available with Trip Pro

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. The NPPA gene codes for the precursor of atrial natriuretic polypeptide, suggesting that NPPA may modulate the efficacy of some antihypertensive drugs.To test whether participants with minor NPPA alleles in the T2238C or G664A variants had different rates of cardiovascular disease or blood pressure (BP) changes than common allele homozygotes when treated (...) ).The primary outcome measure was coronary heart disease (CHD), defined as fatal CHD or nonfatal myocardial infarction (mean follow-up, 4.9 years). Secondary outcomes were stroke, all-cause mortality, combined cardiovascular disease outcomes, and 6-month systolic and diastolic BP changes. Genotype x treatment interactions were tested where genotypes were modeled additively and dominantly.Depending on genotype, the event rates per 1000 person-years were 15.3 to 19.7 for CHO, 9.6 to 15.4 for stroke, and 27.4

2008 JAMA

730. Cardiovascular disease: identifying and supporting people most at risk of dying early

Cardiovascular disease: identifying and supporting people most at risk of dying early Cardio Cardiovascular disease: identifying and vascular disease: identifying and supporting people most at risk of dying supporting people most at risk of dying early early Public health guideline Published: 24 September 2008 nice.org.uk/guidance/ph15 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) Advisory Committee (PHIAC) 28 NICE project team 30 Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 57External contractors 31 Fieldwork 31 Appendix B: Summary of the methods used to develop this guidance 32 Introduction 32 The guidance development process 32 Key questions 33 Reviewing the evidence of effectiveness 33 Study

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines

731. Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk Full Text available with Trip Pro

modification should be considered an important component of the medical management of patients to reduce the risk of both CVD and T2DM. Summary of Recommendations The dramatic increase in the incidence of patients at risk for the development of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) throughout the developed and developing world requires that physicians and other care providers be aware of the risk factors for these conditions and be able to identify patients at risk in order (...) Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search

2008 The Endocrine Society

732. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlle (Abstract)

Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlle Our aim was to investigate whether a nurse-coordinated multidisciplinary, family-based preventive cardiology programme could improve standards of preventive care in routine clinical practice.In a matched, cluster-randomised, controlled trial (...) in eight European countries, six pairs of hospitals and six pairs of general practices were assigned to an intervention programme (INT) or usual care (UC) for patients with coronary heart disease or those at high risk of developing cardiovascular disease. The primary endpoints-measured at 1 year-were family-based lifestyle change; management of blood pressure, lipids, and blood glucose to target concentrations; and prescription of cardioprotective drugs. Analysis was by intention to treat. The trial

2008 Lancet Controlled trial quality: predicted high

733. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. Full Text available with Trip Pro

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. Recent randomized trials among patients with preexisting cardiovascular disease (CVD) have failed to support benefits of B-vitamin supplementation on cardiovascular risk. Observational data suggest benefits may be greater among women, yet women have been underrepresented in published randomized trials.To test whether a combination (...) ). In a blood substudy, geometric mean plasma homocysteine level was decreased by 18.5% (95% CI, 12.5%-24.1%; P < .001) in the active group (n = 150) over that observed in the placebo group (n = 150), for a difference of 2.27 micromol/L (95% CI, 1.54-2.96 micromol/L).After 7.3 years of treatment and follow-up, a combination pill of folic acid, vitamin B6, and vitamin B12 did not reduce a combined end point of total cardiovascular events among high-risk women, despite significant homocysteine

2008 JAMA Controlled trial quality: predicted high

734. Secondary prevention of cardiovascular disease with statins. How far should we go?

Secondary prevention of cardiovascular disease with statins. How far should we go? Volumen 16. DTB Navarre. Vol 16, No 2. March - April 2008 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB Navarre. Vol 16, No 2. March - April 2008 DTB Navarre. Vol 16, No 2. March - April 2008 Content tools Share it Secondary prevention of cardiovascular disease with statins. How far should we go? The use of statins has shown a reduction in cardiovascular (...) morbidity and mortality in patients with coronary and atherosclerotic disease for different levels of cholesterol. Intensive treatment with high dose statins to obtain low levels of LDL-c (70-80 mg/dL or 1.8-2.0 mmol/L) in patients with stable coronary disease has shown only scarce benefits in selected patients and in composite endpoints with dubious justification. These benefits are small and there is no improvement in survival of patients with coronary disease. Intensive therapy notably increases

2008 Drug and Therapeutics Bulletin of Navarre (Spain)

735. Buflomedil reduced cardiovascular events in peripheral arterial disease

Buflomedil reduced cardiovascular events in peripheral arterial disease Buflomedil reduced cardiovascular events in peripheral arterial disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Buflomedil reduced cardiovascular events in peripheral arterial disease Article Text Therapeutics Buflomedil reduced cardiovascular events in peripheral arterial disease Statistics from Altmetric.com A Leizorovicz Dr A Leizorovicz, Service de

2008 Evidence-Based Medicine

736. Grand Rounds: Novel Applications of Erythropoietin in Cardiovascular Disease

Grand Rounds: Novel Applications of Erythropoietin in Cardiovascular Disease Grand Rounds: “Novel Applications of Erythropoietin in Cardiovascular Disease” – Clinical Correlations Search Grand Rounds: “Novel Applications of Erythropoietin in Cardiovascular Disease” October 22, 2008 3 min read Commentary by Srikant Duggirala MD, PGY-2 Please also see the presented during this week’s grand rounds On Wednesday, October, 15, 2008, the NYU Department of Medicine Grand Rounds featured one of its own (...) guest speakers, Stuart Katz M.D., Professor of Medicine and Director of Heart Failure at NYU School of Medicine, with his lecture entitled “Novel Applications of Erythropoietin in Cardiovascular Disease.” Dr. Katz began his lecture with a discussion of oxygen uptake in a various individuals such as elite athletes and comparing their oxygen uptake ability to average individuals and also to heart failure patients. An elite athlete such as Lance Armstrong has an average maximum oxygen uptake 82ml/kg

2008 Clinical Correlations

737. QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk

QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated riskCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated riskCommentary Article Text Clinical

2008 Evidence-Based Nursing

738. Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI

Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2

2008 Evidence-Based Medicine

739. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

740. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized place

Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized place Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis (...) of randomized placebo-controlled clinical trials Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials Saha S A, Molnar J, Arora R R CRD summary The authors concluded that tissue angiotensin-converting enzyme inhibitors appear to modestly reduce the risk of myocardial infarction

2008 DARE.